Patents by Inventor Hendri Tjandra

Hendri Tjandra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY MANUFACTURE
    Publication number: 20230221334
    Abstract: Described herein is a method for assessing disulfide bond reduction potential of a protein of interest comprising the following steps: Providing a cell culture fluid sample comprising mammalian cells expressing a protein of interest at a concentration within the range of between 0.2 g/l to 10 g/l Filtering said cell culture fluid sample over at least one filter Displacing O2 in the filtered cell culture fluid sample Collecting at least one sample of the O2-displaced filtered cell culture fluid sample Separating the proteins in said at least one O2-displaced, filtered cell culture fluid sample according to their size under non-denaturing conditions Determining the disulfide bond reduction potential of the protein of interest.
    Type: Application
    Filed: January 13, 2023
    Publication date: July 13, 2023
    Inventors: Hendri TJANDRA, Yi LIU, Vu THAI
  • Factor VIII conjugates
    Patent number: 9364520
    Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: June 14, 2016
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Clark Q. Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
  • METHODS OF TREATING HEMOPHILIA IN PATIENTS HAVING DEVELOPED INHIBITORY ANTIBODIES
    Publication number: 20160051633
    Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
    Type: Application
    Filed: July 20, 2015
    Publication date: February 25, 2016
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Clark Q. PAN, John E. MURPHY, Baisong MEI, Jonathan S. STRAUSS, Hendri TJANDRA, Jianmin CHEN, Thomas BARNETT, Liang TANG, Deqian WANG
  • Factor VIII conjugates
    Patent number: 9096656
    Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: August 4, 2015
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Clark Q. Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
  • FACTOR VIII CONJUGATES
    Publication number: 20130274445
    Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
    Type: Application
    Filed: January 24, 2013
    Publication date: October 17, 2013
    Inventors: Clark Q Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
  • CONTINUATION - SITE DIRECTED MODIFICATION OF FVIII
    Publication number: 20100081615
    Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
    Type: Application
    Filed: August 13, 2009
    Publication date: April 1, 2010
    Applicant: Bayer HealthCare LLC
    Inventors: Clark Q. Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
  • Site-directed modification of FVIII
    Patent number: 7632921
    Abstract: This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: December 15, 2009
    Assignee: Bayer Healthcare LLC
    Inventors: Clark Q. Pan, John E. Murphy, Baisong Mei, Jonathan S. Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang
  • Site-directed modification of FVIII
    Publication number: 20060115876
    Abstract: This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
    Type: Application
    Filed: November 14, 2005
    Publication date: June 1, 2006
    Applicant: Bayer HealthCare LLC
    Inventors: Clark Pan, John Murphy, Baisong Mei, Jonathan Strauss, Hendri Tjandra, Jianmin Chen, Thomas Barnett, Liang Tang, Deqian Wang